Maxwell Biomedical, founded with the mission to revolutionize cardiac care, focuses on developing advanced medical devices for the shock-free termination of atrial fibrillation (AF). Their flagship product monitors, diagnoses, and performs anti-AFib pacing called SRT to restore normal sinus rhythm without the need for painful shocks. The company aims to improve outcomes for patients suffering from both atrial fibrillation and heart failure, conditions that often coexist and exacerbate each other.

Notable figures associated with Maxwell Biomedical include leading cardiologists and biomedical engineers who have contributed to its innovative approach. The company has attracted significant investment from prominent venture capital firms in the healthcare sector. Key achievements include successful clinical trials demonstrating the efficacy and safety of their device. Maxwell Biomedical's impact lies in offering a less invasive, more patient-friendly solution to managing atrial fibrillation, potentially reducing risks such as stroke and heart failure hospitalization.